Modulating Cardiac Energetics in Cardio-Metabolic Syndromes: A mechanistic, hyperpolarized MR Trial of Ninerafaxstat Treatment
Year: 2024
Type: preprint
Study design: Clinical Trial
Abstract: Background Type 2 diabetes (T2D) and obesity are key contributors for heart failure (HF)- development, especially for HF with a preserved ejection fraction (HFpEF). On a molecular basis, excessive use of fatty acids (FA) induces lipotoxicity which in turn promotes inflammation, reduces mitochondrial pyruvate dehydrogenase (PDH) activity and impairs myocardial energetics and -function. Harnessing in-vivo, real time measurement of cellular metabolism via hyperpolarized pyruvate MR, we aimed to assess the effects of ninerafaxstat, a selective FA oxidation inhibitor, on cardiac energetics, metabolism & diastolic function in patients with cardio-metabolic syndromes. Methods IMPROVE-DiCE was an open-label, mechanistic phase 2a trial. 21 participants received 200mg ninerafaxstat twice daily for four (n=5) or eight weeks (n=16). Myocardial energetics (phosphocreatine to adenosine triphosphate ratio, PCr/ATP), metabolism and function were assessed pre-& post-treatment using magnetic resonance imaging (MRI), 31 P- and 1 H-MR spectroscopy (MRS). We utilised hyperpolarized [1- 13 C]pyruvate MRS to assess in-vivo PDH-flux (n=9) and plasma metabolomics and proteomics to assess whole body metabolism. Results Patients presented with impaired PCr/ATP, (median 1.6 [IQR 1.4, 2.1]), myocardial steatosis (2.2 % [IQR 1.5, 3.2]) and LV diastolic dysfunction (peak circumferential diastolic strain rate 0.86/s [IQR 0.82, 1.06]) at baseline. Ninerafaxstat treatment improved myocardial energetics by 32% ( p <0.01), reduced myocardial triglyceride content by 34% ( p =0.03) and showed a trend towards improved PDH-flux (mean 45% increase, p =0.08). Diastolic function was significantly improved post-treatment (peak diastolic strain rate by 10%, peak LV filling rate by 11%, both p <0.05). Conclusions Metabolic modulation with ninerafaxstat significantly improved myocardial energetics, reduced myocardial steatosis and improved LV diastolic filling. Combining hyperpolarized MRS and metabolomics, is a powerful approach to examine the mechanism of action of novel metabolic modulators. REGISTRATION URL: https://clinicaltrials.gov ; Unique identifier: NCT04826159 Abstract Figure
Authors: Moritz. J. Hundertmark, Adrienne. G. Siu, Violet Matthews, Andrew J. Lewis, James Grist, Jai Patel, Paul Chamberlin, Rizwan Sarwar, Arash Yavari, Hakim-Moulay Dehbi, Prashant Rao, Xu Shi, Shuning Zheng, Jeremy M. Robbins, Robert E. Gerszten, Michael P. Frenneaux, Ladislav Valkovič, Jack J.J.J Miller, Stefan Neubauer, Damian J. Tyler, Oliver J. Rider
Institutions: University Hospital of Bern, John Radcliffe Hospital, University of Oxford, Oxford University Hospitals NHS Trust, University of Birmingham, University College London, Beth Israel Deaconess Medical Center, Hamad Medical Corporation, Slovak Academy of Sciences, Institute of Measurement Science of the Slovak Academy of Sciences, Aarhus University
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: Medpace, Wellcome Trust, National Institute for Health and Care Research, British Heart Foundation, Department of Health and Social Care, University of Oxford, Novo Nordisk, Agentúra na Podporu Výskumu a Vývoja, Vedecká Grantová Agentúra MŠVVaŠ SR a SAV, NIHR Oxford Biomedical Research Centre
Awards: Increasing substrate supply to the heart as a therapeutic strategy in heart failure, G22512508, Zobrazovacie metódy na báze magnetickej rezonancie pre medicínsku diagnostiku a materiálový výskum., Novel multi-nuclear magnetic resonance spectroscopy approaches for the sensitive and robust assessment of human cardiac energetics
OpenAlex ID: W4395673131
